Verve Therapeutics Inc is a biotechnology business based in the US. Verve Therapeutics shares (VERV) are listed on the NASDAQ and all prices are listed in US Dollars. Verve Therapeutics employs 113 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Verve Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VERV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Verve Therapeutics stock price (NASDAQ: VERV)
Use our graph to track the performance of VERV stocks over time.Verve Therapeutics shares at a glance
Latest market close | $15.50 |
---|---|
52-week range | $10.70 - $78.00 |
50-day moving average | $14.69 |
200-day moving average | $31.33 |
Wall St. target price | $53.83 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.58 |
Buy Verve Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Verve Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Verve Therapeutics price performance over time
Historical closes compared with the close of $15.5 from 2022-06-29
1 week (2022-06-24) | -8.28% |
---|---|
1 month (2022-06-01) | 7.34% |
3 months (2022-04-01) | -31.14% |
6 months (2021-12-31) | -57.96% |
1 year (2021-07-01) | -70.83% |
---|---|
2 years (2020-06-27) | N/A |
3 years (2019-06-27) | N/A |
5 years (2017-06-27) | N/A |
Verve Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -25.85% |
Return on equity TTM | -57.91% |
Profit margin | 0% |
Book value | $6.81 |
Market capitalisation | $822.4 million |
TTM: trailing 12 months
Verve Therapeutics share dividends
We're not expecting Verve Therapeutics to pay a dividend over the next 12 months.
Verve Therapeutics overview
Verve Therapeutics, Inc. , a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc. ; a development and option agreement with Acuitas Therapeutics, Inc. ; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
Verve Therapeutics in the news
Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors
Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
Frequently asked questions
What percentage of Verve Therapeutics is owned by insiders or institutions?Currently 35.389% of Verve Therapeutics shares are held by insiders and 80.071% by institutions. How many people work for Verve Therapeutics?
Latest data suggests 113 work at Verve Therapeutics. When does the fiscal year end for Verve Therapeutics?
Verve Therapeutics's fiscal year ends in December. Where is Verve Therapeutics based?
Verve Therapeutics's address is: 500 Technology Square, Cambridge, MA, United States, 02139 What is Verve Therapeutics's ISIN number?
Verve Therapeutics's international securities identification number is: US92539P1012
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert